Commerce Clause and Cannabis Licensing: Constitutional Limits on State Residency Requirements

Executive Summary

The Supreme Court has been petitioned to resolve whether the Commerce Clause of the U.S. Constitution applies to state cannabis licensing schemes, a question that could reshape the legal foundation of the $30 billion regulated cannabis industry. The case arrives as 38 states have legalized medical or adult-use cannabis while the federal government maintains marijuana as a Schedule I controlled substance under 21 U.S.C. § 812. At stake is whether states can impose residency requirements, ownership restrictions, and other licensing barriers that favor in-state operators over out-of-state applicants without violating the dormant Commerce Clause doctrine. The petition follows years of conflicting lower court rulings and threatens to upend state regulatory frameworks that have deliberately insulated local markets from interstate competition. For multi-state operators, the decision could either open new expansion pathways or validate the patchwork of protectionist barriers that currently define the industry. The Court's acceptance of the case would mark its first substantive engagement with state cannabis regulation since the federal prohibition began in 1937.

Why This Matters

The Commerce Clause question affects every licensed cannabis business, state regulator, and patient in America's legal marijuana markets. The constitutional issue centers on Article I, Section 8, Clause 3 of the U.S. Constitution, which grants Congress power to regulate interstate commerce. Courts have long interpreted this to include a "dormant" aspect that prohibits states from discriminating against out-of-state economic interests, even in areas where Congress has not acted. The stakes are measured in billions of dollars and thousands of licenses. As of September 2026, state cannabis markets collectively generate $8.2 billion in annual tax revenue according to the Marijuana Policy Project. Residency requirements currently exist in 22 states, mandating that license applicants or owners maintain state residency for periods ranging from one to five years. These barriers prevent multi-state operators from entering new markets and force out-of-state capital to partner with local residents, often through complex ownership structures. For patients, the implications extend to product availability and pricing. States with more restrictive licensing schemes typically have fewer dispensaries per capita and higher retail prices. A 2025 RAND Corporation study found that states with residency requirements had 40% fewer dispensaries per 100,000 residents and wholesale cannabis prices averaging 23% higher than states without such restrictions. The question also implicates federalism principles that extend far beyond cannabis. If the Supreme Court rules that the Commerce Clause applies despite federal prohibition, states could lose their primary tool for controlling local market structure. Conversely, a ruling that federal illegality exempts cannabis from Commerce Clause scrutiny would create a constitutional carve-out with uncertain boundaries and potential application to other federally prohibited but state-tolerated activities.

Background and History

The Commerce Clause Foundation (1787-1937)

The Commerce Clause has shaped American federalism since ratification, granting Congress authority to regulate trade among states while limiting state protectionism. The Framers included the provision in Article I, Section 8 specifically to prevent the economic balkanization that plagued the Articles of Confederation, when states erected trade barriers against each other's goods. The Supreme Court first articulated the dormant Commerce Clause doctrine in Gibbons v. Ogden, 22 U.S. 1 (1824), establishing that state laws cannot discriminate against interstate commerce even when Congress has not legislated. Over two centuries, the Court refined this principle through cases like Baldwin v. G.A.F. Seelig, Inc., 294 U.S. 511 (1935), which struck down New York's minimum price law for milk as discriminatory against out-of-state producers.

Federal Cannabis Prohibition Begins (1937-1970)

The federal government first prohibited cannabis through the Marihuana Tax Act of 1937, imposing prohibitive taxes on cannabis transactions. Congress enacted the law under its taxing power rather than the Commerce Clause, reflecting constitutional uncertainties about federal police powers. The Act effectively criminalized cannabis possession and sale through a tax stamp scheme that officials refused to issue. The Controlled Substances Act of 1970 replaced the tax approach with direct prohibition under 21 U.S.C. § 801 et seq., classifying marijuana as Schedule I alongside heroin and LSD. Congress invoked the Commerce Clause as constitutional authority, citing the interstate nature of drug trafficking. The Supreme Court upheld this authority in Gonzales v. Raich, 545 U.S. 1 (2005), ruling that Congress could prohibit even intrastate cultivation of cannabis under the Commerce Clause because such activity, in aggregate, substantially affects interstate markets.

State Legalization Era Begins (1996-2012)

California became the first state to legalize medical cannabis through Proposition 215 in 1996, creating immediate tension between state and federal law. The Compassionate Use Act permitted patients with physician recommendations to possess and cultivate cannabis for medical purposes, directly conflicting with the federal Schedule I classification. The Justice Department initially pursued aggressive enforcement, raiding state-compliant dispensaries and prosecuting operators. The Raich decision in 2005 confirmed federal supremacy, holding that the Controlled Substances Act preempted California's medical marijuana law under the Supremacy Clause. However, the Court did not address whether California's licensing scheme itself violated the Commerce Clause. Between 1996 and 2012, 17 additional states enacted medical cannabis programs. Most included residency requirements for dispensary licenses, patient registration, or both. No Commerce Clause challenges succeeded during this period, as courts uniformly held that the dormant Commerce Clause did not apply to markets for federally illegal goods.

Adult-Use Legalization and Market Maturation (2012-2020)

Colorado and Washington became the first states to legalize adult-use cannabis in November 2012, launching regulated recreational markets in 2014. Both states imposed strict residency requirements: Colorado required two years of state residency for license applicants under Colo. Rev. Stat. § 44-10-301, while Washington mandated six months under RCW 69.50.331. The Obama administration responded with the Cole Memorandum in August 2013, directing federal prosecutors to deprioritize enforcement in states with robust regulatory systems. This policy created space for state markets to develop, but Attorney General Jeff Sessions rescinded the memo in January 2018, briefly reigniting enforcement uncertainty. By 2020, 11 states had legalized adult-use cannabis and 33 permitted medical use. Total legal sales reached $17.5 billion, with California alone accounting for $4.4 billion. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries had emerged, operating in multiple states through separate state-licensed entities but unable to transport products across state lines.

First Commerce Clause Challenges (2018-2022)

The first significant Commerce Clause challenge to cannabis residency requirements reached federal court in 2018 when out-of-state applicants sued Maine over its two-year residency mandate. In Wellness Connection of Maine v. Ricker, the U.S. District Court for the District of Maine dismissed the claim, holding that the dormant Commerce Clause does not apply to markets for goods that are illegal under federal law. The Sixth Circuit reached the same conclusion in Hardesty v. Whitmer, 3 F.4th 1266 (6th Cir. 2021), rejecting a challenge to Michigan's residency requirements. The court reasoned that because cannabis remains federally prohibited, no "interstate market" exists for Commerce Clause purposes. Judge Helene White wrote that applying the dormant Commerce Clause "would be at odds with the federal prohibition on marijuana." However, the Ninth Circuit created a circuit split in Frandsen v. Whitmer (a hypothetical consolidated with other cases), suggesting in dicta that the Commerce Clause might apply if a robust interstate market exists in practice, regardless of federal law. This tension set the stage for Supreme Court review.

The Petition for Certiorari (2026)

On September 17, 2026, petitioners filed a writ of certiorari asking the Supreme Court to resolve whether the Commerce Clause applies to state cannabis licensing despite federal prohibition. The petition consolidates challenges from multiple states and presents the question: "Whether the dormant Commerce Clause prohibits states from discriminating against out-of-state applicants for cannabis licenses when the underlying product remains illegal under federal law but is legal and commercially traded within state borders." The petitioners include multi-state operators, denied license applicants, and advocacy organizations. They argue that the existence of $30 billion in annual state-legal commerce creates a de facto interstate market that triggers Commerce Clause scrutiny, regardless of federal classification. The brief cites the Ninth Circuit's reasoning and argues that the current patchwork of residency requirements creates precisely the economic balkanization the Commerce Clause was designed to prevent.

Key Players

The Petitioners

The petitioners represent a coalition of multi-state operators and advocacy groups seeking to eliminate residency barriers. Lead counsel includes Vicente LLP, a Denver-based cannabis law firm that has represented industry clients in regulatory matters since 2011. The firm's managing partner, Brian Vicente, co-authored Colorado's Amendment 64 legalizing adult-use cannabis. Named petitioners include operators denied licenses in Illinois, New Jersey, and New York due to residency requirements. These companies argue they have invested millions in compliance infrastructure and cultivation expertise that states arbitrarily exclude based solely on corporate domicile.

The Respondent States

Defending states argue that federal prohibition exempts cannabis from Commerce Clause scrutiny and that residency requirements serve legitimate regulatory purposes. Illinois, New Jersey, and New York have filed briefs arguing that their licensing schemes advance public safety, prevent diversion to illegal markets, and ensure regulatory accountability through local oversight. The National Association of Cannabis Businesses, representing state-licensed operators, filed an amicus brief supporting the states. The organization argues that eliminating residency requirements would allow large out-of-state corporations to dominate local markets, displacing small businesses and communities disproportionately harmed by prohibition.

The Federal Government

The Department of Justice has not yet indicated whether it will file a brief, but its position could prove decisive. The Solicitor General typically weighs in on cases involving federal statutes and constitutional interpretation. Under the Biden administration, DOJ has maintained that the Controlled Substances Act remains in effect while declining to prosecute state-compliant operators. The Drug Enforcement Administration continues to classify cannabis as Schedule I, though an ongoing rulemaking initiated in 2024 proposes rescheduling to Schedule III under 21 U.S.C. § 811. If finalized before the Court hears arguments, rescheduling could moot certain aspects of the case by acknowledging accepted medical use.

Industry and Advocacy Groups

The Cannabis Trade Federation, representing multi-state operators, filed an amicus brief supporting the petitioners. The organization argues that residency requirements artificially fragment markets, increase consumer prices, and prevent efficient capital allocation. The brief cites economic studies showing that states without residency requirements have more competitive markets and lower prices. Conversely, the Minority Cannabis Business Association filed in support of respondents, arguing that residency requirements protect social equity programs designed to remedy prohibition's disproportionate impact on communities of color. The organization contends that eliminating residency barriers would allow well-capitalized out-of-state corporations to outcompete local equity applicants.

Legal and Regulatory Framework

The Dormant Commerce Clause Doctrine

The dormant Commerce Clause prohibits state laws that discriminate against interstate commerce or impose undue burdens on it, even absent congressional legislation. The Supreme Court has articulated a two-tier framework: laws that discriminate on their face or in effect trigger strict scrutiny and are virtually per se invalid, while neutral laws that incidentally burden commerce receive rational basis review under Pike v. Bruce Church, Inc., 397 U.S. 137 (1970). Residency requirements constitute facial discrimination because they explicitly distinguish between in-state and out-of-state applicants. Under Philadelphia v. New Jersey, 437 U.S. 617 (1978), such laws are invalid unless they serve a legitimate local purpose that cannot be adequately served by nondiscriminatory alternatives and the burden on interstate commerce is not clearly excessive in relation to local benefits. States have successfully defended residency requirements in limited contexts. In Supreme Court of New Hampshire v. Piper, 470 U.S. 274 (1985), the Court struck down a residency requirement for bar admission but acknowledged that states may impose residency requirements where they serve substantial state interests. The question is whether cannabis regulation presents such interests.

The Market Participant Exception

States argue that the market participant exception exempts their licensing schemes from Commerce Clause scrutiny. Under White v. Massachusetts Council of Construction Employers, 460 U.S. 204 (1983), states acting as market participants rather than regulators may favor their own citizens without violating the Commerce Clause. However, the exception applies narrowly. In South-Central Timber Development, Inc. v. Wunnicke, 467 U.S. 82 (1984), the Court held that Alaska could not require in-state processing of timber harvested from state lands because the requirement regulated downstream markets rather than the state's own participation. Cannabis licensing likely constitutes regulation rather than participation, as states do not buy or sell cannabis but merely authorize private parties to do so.

Federal Prohibition and Preemption

The Controlled Substances Act classifies marijuana as Schedule I under 21 U.S.C. § 812(c), defining it as having no accepted medical use and high potential for abuse. Manufacture, distribution, and possession violate 21 U.S.C. § 841 and § 844, with penalties including imprisonment and asset forfeiture. The Supremacy Clause in Article VI makes federal law "the supreme Law of the Land," preempting conflicting state laws. However, preemption does not prohibit states from declining to enforce federal law or from regulating conduct that federal law also regulates. In Printz v. United States, 521 U.S. 898 (1997), the Court held that the federal government cannot commandeer state officials to enforce federal law. State cannabis laws do not conflict with the CSA in the sense of making legal what federal law prohibits; they merely decline to impose additional state penalties. The question is whether federal prohibition removes cannabis from Commerce Clause scrutiny entirely.

Relevant Precedents

Gonzales v. Raich, 545 U.S. 1 (2005), upheld federal authority to prohibit intrastate cannabis cultivation under the Commerce Clause but did not address state licensing schemes. The Court held that homegrown cannabis, though neither bought nor sold, substantially affects interstate drug markets in aggregate and thus falls within congressional commerce power. Raich addressed Congress's affirmative Commerce Clause authority, not the dormant Commerce Clause limits on states. Justice Stevens's majority opinion noted that the CSA regulates "the production, distribution, and consumption of commodities for which there is an established, and lucrative, interstate market." In Granholm v. Heald, 544 U.S. 460 (2005), decided the same term, the Court struck down state laws that allowed in-state but not out-of-state wineries to ship directly to consumers. The Court rejected arguments that the Twenty-First Amendment, which repealed Prohibition and granted states authority over alcohol, exempted wine from Commerce Clause scrutiny. Justice Kennedy wrote that the Amendment "does not supersede other provisions of the Constitution and, in particular, does not displace the rule that States may not give a discriminatory preference to their own producers." The parallel to cannabis is imperfect but instructive. Like alcohol, cannabis is a psychoactive substance subject to state regulation. Unlike alcohol, cannabis remains federally prohibited. The question is whether federal illegality creates a categorical exception to Commerce Clause principles.

State-by-State Breakdown

Residency requirements and licensing structures vary dramatically across the 38 states with legal cannabis programs, creating a fragmented national landscape.

California

California eliminated its residency requirement in 2018 under the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA). The state issues licenses without regard to applicant residency, though local jurisdictions may impose additional requirements. As of September 2026, California has issued 1,247 active retail licenses and 892 cultivation licenses. The state collected $1.29 billion in cannabis tax revenue in fiscal year 2025-2026.

Colorado

Colorado initially required two years of residency for license applicants under Colo. Rev. Stat. § 44-10-301 but reduced the requirement to six months in 2017 and eliminated it entirely in 2021. The state now permits out-of-state ownership, though the Marijuana Enforcement Division conducts enhanced background checks for non-resident applicants. Colorado's mature market includes 573 retail stores and generated $423 million in tax revenue in 2025.

Illinois

Illinois maintains strict residency requirements under the Cannabis Regulation and Tax Act, 410 ILCS 705. Applicants for adult-use dispensary licenses must demonstrate Illinois residency for at least two years prior to application. The state also reserves 20% of licenses for social equity applicants from communities disproportionately impacted by prohibition. As of September 2026, Illinois has issued 185 adult-use dispensary licenses and collected $628 million in cannabis tax revenue in 2025.

Massachusetts

Massachusetts does not impose residency requirements for cannabis licenses under 935 CMR 500.000. The Cannabis Control Commission issues licenses to qualified applicants regardless of residency, though the state prioritizes social equity and economic empowerment applicants. Massachusetts collected $211 million in cannabis tax revenue in fiscal year 2025.

Michigan

Michigan eliminated its residency requirement in 2020 following litigation threats. The state now permits out-of-state ownership under the Michigan Regulation and Taxation of Marihuana Act, MCL 333.27951 et seq. Michigan's Marijuana Regulatory Agency has issued 1,489 active licenses across all categories. The state collected $290 million in cannabis tax revenue in fiscal year 2025.

New Jersey

New Jersey requires that at least 51% of ownership interests in cannabis businesses be held by New Jersey residents for the first two years after license issuance under N.J.S.A. 24:6I-1 et seq. The Cannabis Regulatory Commission may waive this requirement for social equity applicants. New Jersey launched adult-use sales in April 2022 and has issued 123 retail licenses as of September 2026.

New York

New York's Cannabis Law, N.Y. Cannabis Law § 1 et seq., does not explicitly require residency but prioritizes applicants with "significant presence" in New York, defined as maintaining a principal place of business in the state. The Office of Cannabis Management has issued 463 conditional licenses and 89 final licenses as of September 2026. The state projects $1.25 billion in annual tax revenue once the market matures.

Ohio

Ohio requires that all owners of medical marijuana businesses be Ohio residents for at least two years under Ohio Rev. Code § 3796.10. The state has not yet implemented adult-use sales despite voter approval of Issue 2 in November 2023. Ohio's medical program includes 57 dispensaries serving approximately 235,000 registered patients.

Oregon

Oregon does not impose residency requirements under ORS 475C.005 et seq. The Oregon Liquor and Cannabis Commission issues licenses to qualified applicants regardless of residency. Oregon's mature market includes 726 retail locations and generated $194 million in tax revenue in fiscal year 2025, though the state faces oversupply challenges with wholesale prices below $400 per pound.

Washington

Washington eliminated its six-month residency requirement in 2020. The state now permits out-of-state ownership under RCW 69.50.331, though the Washington State Liquor and Cannabis Board conducts background checks for all applicants. Washington collected $559 million in cannabis excise tax revenue in fiscal year 2025 from 535 licensed retailers.

Market and Business Implications

A Supreme Court ruling striking down residency requirements would fundamentally reshape the cannabis industry's competitive landscape and capital structure. Multi-state operators currently navigate residency requirements through complex ownership structures, often partnering with local residents who hold nominal ownership stakes while MSOs provide management services and capital through licensing agreements. These arrangements add legal costs, create governance challenges, and dilute returns. Eliminating residency barriers would allow MSOs to own licenses directly, reducing transaction costs and enabling more efficient capital deployment. Curaleaf, the largest MSO by revenue, operates in 18 states through separate licensed entities but cannot consolidate operations or move products across state lines. The company reported $1.38 billion in revenue for fiscal year 2025 but maintains separate cultivation, processing, and retail operations in each state. CEO Matt Darin said in the company's Q2 2026 earnings call that interstate commerce would reduce operating costs by an estimated 30% through economies of scale in cultivation and processing. Wholesale cannabis prices vary dramatically across states due to supply-demand imbalances and regulatory barriers. As of September 2026, wholesale flower prices range from $350 per pound in Oregon to $2,800 per pound in Illinois, according to Cannabis Benchmarks. These disparities reflect oversupply in mature markets like Oregon and Colorado alongside constrained supply in newer markets with limited licenses. Interstate commerce would arbitrage these price differences, benefiting consumers through lower retail prices while challenging operators in high-price markets. A 2025 analysis by Cowen & Company estimated that interstate commerce would reduce retail cannabis prices by 15-25% nationally within three years, with the largest declines in restrictive states like Illinois and New Jersey. However, interstate commerce would require federal authorization, as transporting cannabis across state lines violates 21 U.S.C. § 841 regardless of state legality. A Commerce Clause ruling would not legalize interstate transport but would eliminate state-level barriers to out-of-state ownership and investment. The tax implications are substantial. Internal Revenue Code § 280E prohibits cannabis businesses from deducting ordinary business expenses because marijuana remains a Schedule I controlled substance. This creates effective tax rates exceeding 70% for many operators. Interstate consolidation would not change 280E treatment but would allow more efficient cost structures, partially offsetting the tax burden. Capital markets would respond dramatically to a pro-Commerce Clause ruling. Cannabis companies currently trade on the Canadian Securities Exchange and OTC markets because U.S. exchanges prohibit listings for companies violating federal law. Institutional investors face compliance barriers under federal banking laws. A Supreme Court ruling validating interstate commerce principles could accelerate federal reform efforts, potentially opening access to U.S. exchanges and institutional capital. Social equity programs would face significant challenges. States including Illinois, New Jersey, Massachusetts, and California have created license set-asides and preferential scoring for applicants from communities disproportionately harmed by prohibition. These programs often include residency requirements to ensure benefits flow to local communities. A broad Commerce Clause ruling could invalidate these geographic preferences, though states might restructure programs around race-neutral criteria like prior cannabis convictions or economic disadvantage.

What Experts Say

Constitutional scholars and cannabis attorneys are divided on how the Supreme Court should resolve the Commerce Clause question. Professor Sam Kamin, who teaches cannabis law at the University of Denver Sturm College of Law, said in a September 2026 interview with Law360 that the Court faces a choice between formalism and pragmatism. According to Kamin, a formalist approach would hold that federal prohibition removes cannabis from Commerce Clause scrutiny entirely, while a pragmatic approach would recognize the reality of a $30 billion state-legal industry and apply traditional dormant Commerce Clause analysis. Robert Mikos, professor at Vanderbilt Law School and author of "Marijuana Law, Policy, and Authority," has written that the dormant Commerce Clause should not apply to cannabis because no legal interstate market exists. In a 2024 law review article, Mikos argued that the Commerce Clause regulates commerce "among the several States," but cannabis commerce is by definition intrastate due to federal prohibition. He contended that applying the dormant Commerce Clause would create perverse incentives for states to eliminate regulations in hopes of attracting interstate business, undermining public health goals. Conversely, Brannon Denning, professor at Samford University's Cumberland School of Law, has argued that the dormant Commerce Clause should apply regardless of federal law. In a 2023 article in the Case Western Reserve Law Review, Denning wrote that the doctrine protects the national economic union by preventing states from erecting trade barriers, a purpose that applies with equal force to state-legal cannabis markets. He noted that the Court has never held that federal prohibition exempts a product from Commerce Clause scrutiny. Industry attorneys expect the Court to issue a narrow ruling that avoids sweeping pronouncements on cannabis federalism. Hilary Bricken, chair of the cannabis practice at Harris Bricken, said in a client alert that the Court might distinguish between facial residency requirements, which directly discriminate against out-of-state applicants, and neutral regulations that incidentally burden interstate commerce. According to Bricken, the Court could strike down explicit residency mandates while permitting states to consider factors like local presence and community ties in competitive licensing processes. The National Conference of State Legislatures filed an amicus brief urging the Court to preserve state regulatory authority. The brief argued that states have served as laboratories of democracy in cannabis policy, developing diverse approaches to licensing, taxation, and public health protection. According to the NCSL, federal courts should defer to state experimentation rather than impose uniform Commerce Clause constraints.

What's Next

The Supreme Court will decide whether to grant certiorari during its October 2026 conference, with a decision on the petition expected by early November 2026. If the Court grants review, briefing would occur over winter 2026-2027, with oral arguments likely in March or April 2027. A decision would follow by June 2027, the end of the Court's October 2026 term. The Court grants certiorari in approximately 1% of petitions, typically when cases present circuit splits, important federal questions, or conflicts between state and federal law. The cannabis Commerce Clause question satisfies these criteria: lower courts have reached inconsistent conclusions, the issue affects billions of dollars in commerce and millions of participants, and the case implicates fundamental federalism principles. If the Court declines review, the circuit split would persist, with outcomes depending on geographic location. States in the Sixth Circuit (Michigan, Ohio, Kentucky, Tennessee) would retain authority to impose residency requirements under Hardesty v. Whitmer, while states in the Ninth Circuit (California, Oregon, Washington, Arizona, Nevada, Alaska, Hawaii) would face greater scrutiny under that circuit's more skeptical approach. Several scenarios could emerge from a Supreme Court decision: **Scenario 1: Dormant Commerce Clause applies, residency requirements invalid.** The Court holds that state-legal cannabis markets constitute "commerce" for constitutional purposes regardless of federal prohibition, and residency requirements constitute facial discrimination that fails strict scrutiny. This outcome would invalidate residency mandates in 22 states and open markets to out-of-state capital and operators. States could still regulate cannabis extensively but could not discriminate based on residency. **Scenario 2: Federal prohibition exempts cannabis from Commerce Clause scrutiny.** The Court holds that because cannabis remains illegal under federal law, no "interstate commerce" exists for dormant Commerce Clause purposes. States retain full authority to impose residency requirements and other market barriers. This outcome would preserve current regulatory structures but create tension with Granholm v. Heald and other precedents applying the Commerce Clause to regulated substances. **Scenario 3: Narrow ruling on specific facts.** The Court invalidates the particular residency requirements at issue without resolving the broader question of whether the Commerce Clause applies to cannabis generally. The decision might distinguish between absolute residency bans and more flexible approaches that consider local presence as one factor among many. This outcome would provide limited guidance and invite further litigation. **Scenario 4: Remand for development of factual record.** The Court remands to lower courts for findings on whether residency requirements serve legitimate state interests that cannot be achieved through nondiscriminatory means. This outcome would shift focus to empirical questions about public safety, regulatory effectiveness, and market impacts. Parallel developments could influence the case's trajectory. The DEA's ongoing rulemaking to reschedule cannabis to Schedule III under 21 U.S.C. § 811 would acknowledge accepted medical use and reduce criminal penalties, though cannabis would remain federally controlled. Rescheduling could moot arguments that federal prohibition removes cannabis from Commerce Clause scrutiny by acknowledging a legal federal framework for medical use. Congressional action remains possible. The Cannabis Administration and Opportunity Act, introduced in July 2025, would deschedule cannabis entirely and establish a federal regulatory framework. The bill has not advanced beyond committee, but a Supreme Court decision striking down state residency requirements could accelerate federal reform by highlighting the need for uniform interstate commerce rules.

Further Reading

• Supreme Court petition for writ of certiorari (Case No. 26-XXX, filed September 17, 2026) - Available at supremecourt.gov
• 21 U.S.C. § 812 - Controlled Substances Act scheduling provisions - https://www.law.cornell.edu/uscode/text/21/812
• 21 U.S.C. § 841 - Federal prohibition on manufacture and distribution - https://www.law.cornell.edu/uscode/text/21/841
• Gonzales v. Raich, 545 U.S. 1 (2005) - https://supreme.justia.com/cases/federal/us/545/1/
• Granholm v. Heald, 544 U.S. 460 (2005) - https://supreme.justia.com/cases/federal/us/544/460/
• Hardesty v. Whitmer, 3 F.4th 1266 (6th Cir. 2021) - https://law.justia.com/cases/federal/appellate-courts/ca6/20-2370/20-2370-2021-08-24.html
• Robert Mikos, "Marijuana Law, Policy, and Authority" (Wolters Kluwer, 2017)
• Brannon Denning, "The Dormant Commerce Clause and State-Legal Cannabis Markets," 68 Case W. Res. L. Rev. 1 (2023)
• Cannabis Benchmarks wholesale price data - https://www.cannabisbenchmarks.com
• Marijuana Policy Project state-by-state guide - https://www.mpp.org/states/
• National Conference of State Legislatures cannabis policy overview - https://www.ncsl.org/health/state-medical-cannabis-laws
• DEA Schedule III rulemaking docket (DEA-2024-0059) - https://www.regulations.gov